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Despite clear associations between vitamin D de-
ficiency and obesity and/or type 2 diabetes, a causal
relationship is not established. Vitamin D receptors
(VDRs) are found within multiple tissues, including the
brain. Given the importance of the brain in controlling
both glucose levels and body weight, we hypothesized
that activation of central VDR links vitamin D to the
regulation of glucose and energy homeostasis. Indeed,
we found that small doses of active vitamin D, 1a,25-
dihydroxyvitamin D3 (1,25D3) (calcitriol), into the third
ventricle of the brain improved glucose tolerance and
markedly increased hepatic insulin sensitivity, an effect
that is dependent upon VDR within the paraventricular
nucleus of the hypothalamus. In addition, chronic central
administration of 1,25D3 dramatically decreased body
weight by lowering food intake in obese rodents. Our data
indicate that 1,25D3-mediated changes in food intake oc-
cur through action within the arcuate nucleus. We found
that VDR colocalized with and activated key appetite-
regulating neurons in the arcuate, namely proopiomelano-
cortin neurons. Together, these findings define a novel
pathway for vitamin D regulation of metabolism with
unique and divergent roles for central nervous system
VDR signaling. Specifically, our data suggest that vitamin
D regulates glucose homeostasis via the paraventricular
nuclei and energy homeostasis via the arcuate nuclei.
Vitamin D is a fat-soluble vitamin available in some foods
but also produced from sunlight. Whatever the source,
vitamin D requires hydroxylation in the liver and kidney
to produce the active form, 1a,25-dihydroxyvitamin D3
(1,25D3), also called calcitriol. 1,25D3 binds to the vitamin
D receptor (VDR), which forms a heterodimer with the
retinoid X receptor and modulates gene expression. Al-
though vitamin D has important roles in calcium/phosphorus
regulation and bone health, it also has important actions
in immunity, inflammation, and differentiation (1).
Interestingly, low vitamin D status is associated with
obesity and impaired glucose tolerance (2,3). Whether this
is a causal relationship is unclear. When combined with
a low-energy diet, vitamin D supplementation results in
greater decreases in body weight and fat mass in humans
(4–6) and prevents dietary-induced weight gain in rodents
(7). Additionally, vitamin D intake at breakfast can in-
crease thermogenesis and fat oxidation rates in subse-
quent meals, suggesting direct metabolic action (8).
Preclinical studies also demonstrate a clear pathway by
which vitamin D affects glucose homeostasis. VDR is pre-
sent in pancreatic b-cells (9), the VDR-null mouse has
impaired glucose tolerance with decreased insulin levels (10),
and supplementation with 1,25D3 improves fasting glucose
levels in mice (11). Given the strong association between
vitamin D status and the metabolic syndrome, the inconsis-
tency of vitamin D supplementation in improving weight or
abnormal glucose tolerance is perplexing (4,12–17).
Understanding how vitamin D might regulate glucose
and body weight is paramount to creating effective
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strategies for using vitamin D in the management of
obesity and diabetes. Previous research has focused on the
peripheral actions of vitamin D. However, the brain, specifi-
cally the hypothalamus, is well-known to control both body
weight and glucose (18). Interestingly, the brain has VDR in key
hypothalamic nuclei including the arcuate (ARC) and paraven-
tricular (PVN) nuclei, which regulate both body weight and
glucose metabolism (19,20). The purpose of this manuscript
is to explore the novel hypothesis that vitamin D regulates
energy and glucose homeostasis via direct actions in the brain.
RESEARCH DESIGN AND METHODS
Animals
Animals were singly housed at the University of Cincinnati
Laboratory Animal Medical Services Facility or at Baylor
College of Medicine (BCM) on a 12-h light/dark cycle with
ad libitum access to water and food. Studies used adult male
Long-Evans rats (Harlan, Indianapolis, IN), mice bearing a
floxed VDR allele (VDRf/f [21]), or C57Bl/6 mice from an
internal colony at BCM. Animal numbers are stated in the
figure legends. All studies were approved by the University
of Cincinnati Institutional Animal Care and Use Committee
(IACUC) or the BCM IACUC as applicable.
Diet
Rats were fed a 40% high-fat butter diet (Research Diets,
New Brunswick, NJ) for at least 13 weeks prior to all
experiments except in the lentiviral studies, which were
performed after 6 weeks of an HFD. Mice were fed a
Western diet (45% fat, cat. no. D12451; Research Diets).
Surgeries
Intracerebroventricular Cannulas
Cannulas were surgically implanted into the third cerebral
ventricle (i3vt) or PVN as previously described (22,23);
coordinates were as follows: i3vt 2.2A/P, 7.8D/V, PVN
1.35A/P, 7.6D/V, and 0.2M/L as determined by the atlas
of Paxinos and Watson (24,25).
Viral Injections
Rats received 2 mL o replication-defective VDR knockdown
lentivirus or its control (SPWGM-V463 [73e6 transducing
units/mL] or SPWGM-NC; Viral Vector Core, University of
South Carolina School of Medicine, Columbia, SC) unilaterally
into the PVN (coordinates as above). Mice received 20 nL
replication-defective adenovirus-associated virus (AAV) con-
taining Cre-recombinase or its control (AAV9.CMV.HI.eGFP-
Cre.WPRE.SV40 9.82e12 genome copies/mL or AAV-CMV-GFP-9
4.0e12 gc/mL; University of Pennsylvania Vector Core, Chapel
Hill, NC) injected bilaterally into the PVN (coordinates
0.94A/P, 4.75D/V, and 0.20M/L). We chose bilateral in-
jection in the mice in order to assess physiologic effects of
vitamin D action in the PVN. At sacrifice, PVN were dis-
sected microscopically and RT-PCR was performed for quan-
tification of VDR. Quantification of VDR knockdown only
occurred in AAV-treated mice, as technical difficulties pre-
vented quantification in lentiviral vector-treated rats.
Carotid/Jugular Catheters
Carotid and jugular catheters were implanted as previously
described with the exception that a mouse antenna for
sampling access was not used (26). Surgery occurred after
13 weeks on HFD.
Drugs
Hydroxypropyl-b-cyclodextrin (THPB-EC; CTD, Inc., Alachua,
FL) was dissolved in saline to a concentration of 0.5 g/mL
and used as the vehicle. 1,25D3 (cat. no. 17936, 1 mg;
Sigma-Aldrich, St. Louis, MO) was dissolved in 0.5 g/mL
hydroxypropyl-b-cyclodextrin. ZK159222, a VDR antagonist
(27,28), was a generous gift from Bayer Pharma AG (Berlin,
Germany) and was dissolved in saline.
Glucose Tolerance Test
Glucose tolerance tests (GTTs) were performed as previously
described (23) with the following modifications: animals fed
the HFD for 18 weeks (Fig. 1A) were fasted for 4 h; intra-
peritoneal GTT (i.p.GTT) used 1.5 g/kg dextrose; 1 h prior to
dextrose administration, body weight–randomized rats were
injected i3vt with 0.1 mg/2 mL 1,25D3 or 2 mL vehicle; and
an additional glucose measurement was performed prior to
the i3vt injection (260 min). This dose was chosen based on
a dose response curve and was the lowest effective dose
(data not shown). For lentiviral studies (Fig. 2D–F), 1 g/kg
dextrose was used and the GTT was performed 4 weeks after
lentiviral injection. Insulin levels during intravenous GTT
(i.v.GTT) were determined with a rat insulin ELISA (Crystal
Chem, Downers Grove, IL). Mouse GTTs were performed
after a 4-h fast with 1.5 g/kg dextrose i.p. No vitamin D
was administered. Insulin levels were not measured dur-
ing i.p.GTTs.
Hyperinsulinemic-Euglycemic Clamp
Rats, which had previously undergone an i.v.GTT the
week before, underwent a hyperinsulinemic-euglycemic
clamp as previously described (23,29) with the following
modifications: animals were fasted for 4 h, and at 120 and
180 min, 0.1 mg/1 mL 1,25D3 or 1 mL vehicle was infused
i3vt. Only animals that were in a steady state at the end
of the clamp were included in the analyses.
Tracer Calculations
Plasma tracer concentrations were determined through a
modification of the Somogyi procedure as previously
published (30,31). Glucose Ra, endogenous glucose pro-
duction, and glucose utilization were calculated according
to previous methods (31,32).
Acute Food Intake Studies
Food intake studies were performed as previously de-
scribed (22) with the modification that rats were injected
i3vt with 0.1 mg/2 mL 1,25D3 or 2 mL vehicle 60 min prior
to dark cycle onset. This dose was used based on the dose
response curve of the GTT.
Chronic Studies
After 20 weeks of HFD, rats underwent i3vt cannula
placement with verification as previously described (22).
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Four weeks later, rats were anesthetized and had osmotic
pump placement (cat. no. 1004; Alzet Osmotic Pumps,
Cupertino, CA) under isoflurane with subcutaneous tubing
connecting the pump to the cannula. Pumps delivered
0.264 mg/day 1,25D3 or 0.11 mL/h vehicle for 28 days.
Food and body weights were measured at 0, 1, 2, 3, 4, 5,
6, 7, 14, 21, and 28 days relative to pump placement. Body
composition was measured with QMR (EchoMRI, Houston,
TX) on days 0 and 29. A second cohort of animals was placed
in a continuous monitoring system (Physioscan Metabolic
Monitoring system, Accuscan Instruments, Columbus, OH) for
96 h to determine energy expenditure 3 days after surgery. We
chose this time point as one where the rats were starting to
recover from surgery but still had similar body weights be-
tween the groups. The first 24 h were considered adaptation,
and the data from the next 72 h were analyzed. Data for
indirect calorimetry analysis were sampled every 10 min.
Immunohistochemistry
Animals
For c-fos studies, ad libitum–fed rats had i3vt cannulas
placed, were allowed to recover for 11 weeks, and were
injected with 2 mL saline or antagonist ZK159222 followed
30 min later by 0.1 mg/1 mL i3vt 1,25D3 or 1 mL vehicle.
They were sacrificed 1 h after injections. VDR location stud-
ies were performed on ad libitum–fed rats without cannulas.
Brain sections were taken from C57Bl/6, neuropeptide Y
(NPY)-GFP, or proopiomelanocortin (POMC)-GFP mice (both
GFP-expressing mice were a generous gift from Yong Xu,
BCM). Animals were deeply anesthetized with ketamine
(70 mg/kg) and xylene (6.2 mg/kg) and perfused trans-
cardially with 0.9% saline followed by 4% formalin. Brains
were stored overnight in 20% sucrose/PBS plus 0.01%
sodium azide at 4°C. Serial coronal sections were collected
at 25 mm and stored in cryopreservative at 220°C.
Immunohistochemistry
Rinses with 0.1 mol/L PBS occurred between each in-
cubation step. Incubations were as follows: 0.3% H2O2/PBS
for 30 min, 0.1 mol/L PBS/3% normal donkey serum/0.25%
Triton-X-100/0.01% sodium azide for 2 h, 1:2,500 rabbit
anti–c-fos (sc52; Santa Cruz Biotechnology, Santa Cruz,
CA) or 1:100 rabbit anti-VDR (N20) (sc-1009; Santa Cruz
Biotechnology) overnight, 1:1,000 biotinylated donkey anti-
rabbit IgG or 1:200 donkey anti-rabbit IgG Alexa Fluor
594 conjugate (A-21207; Thermo Fisher Scientific) in
PBS/3% normal donkey serum/0.25% Triton-X-100 for 2 h,
1:500 avidin biotin complex/PBS solution (PK6100; Vector
Laboratories, Burlingame, CA) for 1 h (c-fos only),
0.04% DAB (D5905; Sigma-Aldrich)/0.01% H2O2/PBS
for 10 min (c-fos only), and PBS plus 0.01% sodium azide;
mounted on slides; air dried overnight; and coverslipped
(vectashield hard-set mounting medium with DAPI used
for slides [101098-050; VWR]). Quantification of c-fos
was performed as previously described (22). An individ-
ual blind to the experimental treatment groups scored
the sections. For determination of the degree of overlap
between cells with GFP expression by POMC and VDR
Figure 1—Hypothalamic 1,25D3 lowers plasma glucose by inhibition of hepatic glucose production. A: i3vt 1,25D3 improves glucose
excursion after an intraperitoneal bolus of dextrose in DIO rats (n = 12 vs. 13). B: Insulin levels were lower in rats treated with i3vt 1,25D3
after a bolus of 0.5 g/kg i.v. dextrose (n = 7–8/group). C–E: HFD-fed rats treated with 0.1 mg i3vt 1,25D3 at 120 and 180 min during a
physiologic hyperinsulinemic-euglycemic clamp had increased glucose infusion rate (C) and during the last 30 min had decreased glucose
production (D) with no change in glucose clearance compared with controls (E) (n = 4–5/group). F: At sacrifice, liver samples from rats
treated with 1,25D3 during the clamp had no change in mRNA expression of g6pc3 but decreased pck1 compared with controls. *P< 0.05.
AUC, area under the curve; Veh, vehicle.
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immunoreactivity, three different sections of the ARC were
examined in each of two separate animals. Mean percent 6
SE of POMC-GFP–expressing cells coexpressing VDR was
determined by averaging the results obtained for each of
the three sections of ARC in the two mice mentioned above.
A similar analysis was done with NPY-GFP–expressing cells.
Display images were adjusted for brightness and contrast.
N20 was chosen as our VDR antibody because it produced
nuclear staining, as opposed to D6 (Santa Cruz Biotechnol-
ogy), which shows cytoplasmic staining in the brain (data
not shown and ref. 33). N20 has been shown to be specific
for the VDR, producing a clear band on Western blots with
absence of staining in a VDR-null animal (34).
Electrophysiology
POMC-CreER/Rosa26-tdTOMATO mice (at 6–10 weeks of
age) were used for electrophysiological recordings as pre-
viously described (35) with the following modifications.
Patch pipettes were filled with intracellular solution (ad-
justed to pH 7.3) containing (in mmol/L) 128 K gluconate,
10 KCl, 10 HEPES, 0.1 EGTA, 2 MgCl2, 0.3 Na-GTP, and
3 Mg-ATP. Current clamp was engaged to test neural firing
frequency at baseline and after puff of 1 mmol/L 1,25D3
for 1 s. The values for firing frequency were averaged
within a 2-min bin at baseline or after 1,25D3 treatment.
Cell Culture
Cells from a mouse neuroblastoma cell line, Neuro-2A
(American Type Culture Collection, Manassas, VA) were
routinely cultured at 37°C in normoxia conditions (5% CO2,
95% air) in DMEM (Life Technologies) supplemented with
10% FBS (Life Technologies) and 1% penicillin-streptomycin.
Cells were plated at 63 105 cells/cm2. At 85–90% confluence,
cells were incubated for 24 h with 1,25D3 (10
27 mol/L) or
vehicle. A separate group also received a VDR antagonist,
ZK159222 (1025 mol/L).
RT-PCR
Quantification of mRNA expression was performed as pre-
viously described (36). TaqMan primers (Thermo Fischer
Scientific) are listed in Supplementary Table 1.
Statistical Analysis
Results are presented as mean 6 SE. Results are analyzed
by a one-way or two-way ANOVA as appropriate with
Figure 2—Vitamin D receptors in PVN are important in regulating glucose. A: The VDR is present in the PVN of HFD-fed rats (310
magnification). B and C: i3vt 1,25D3 increases c-fos in the PVN of DIO rats. This effect is diminished with pretreatment of a VDR antagonist,
ZK159222 (310 magnification). D and E: Intra-PVN 1,25D3 (0.1 mg) 60 min prior to glucose injection tends to improve glucose excursions in
control virus–treated animals (D) but not in animals with VDR shRNA (E) (n = 4–6/group). F: PVN 1,25D3 causes a decrease in the area under
the curve (AUC) in D but not in E. G and H: VDRf/f mice with bilateral PVN knockdown of VDR mediated through AAV-Cre delivery (VDRf/f/
Cre) demonstrate increased glucose excursions after a bolus of 1.5 g/kg i.p. dextrose 16 weeks after AAV-Cre injection from 15–60 min (G)
and in the area under the curve (H) (n = 7–8/group). Dashed lines outline the PVN. Scale bars = 100 mm. *P < 0.05 vs. vehicle or control;
#P < 0.05 vs. antagonist/1,25D3.
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Tukey post hoc analysis where appropriate. The level of
significance was set as P , 0.05. Data were analyzed with
GraphPad Prism, version 6.
RESULTS
Vitamin D and Glucose Regulation in the Brain
For determination of the effect of acute central 1,25D3 admin-
istration on glucose regulation, GTTs and hyperinsulinemic-
euglycemic clamps were performed on HFD rats after
1,25D3 was provided into the third ventricle (i3vt). In
HFD-fed obese rats, i3vt administration of 1,25D3 low-
ered glucose levels during an i.p.GTT at both the 15-min
time point and as measured by the incremental area un-
der the curve (iAUC) (Fig. 1A and inset). This improve-
ment was not observed when the same dose of 1,25D3
was given intraperitoneally, indicating a central effect of
1,25D3 (Supplementary Fig. 1A). Interestingly, we found
that diet had a profound effect on the glucose-regulating
effects of 1,25D3, since there was no effect of i3vt
1,25D3 in chow-fed animals (Supplementary Fig. 1B). As
designed, i3vt 1,25D3 treatment did not alter blood glu-
cose levels during an i.v.GTT (Supplementary Fig. 1C).
However, the insulin response was lower 2 min after glu-
cose injection and as measured by the iAUC (Fig. 1B and
inset). Together, these data indicate that improvements
in glucose levels after 1,25D3 administration were not due
to enhanced insulin secretion. Since glucose clearance dur-
ing an i.v.GTT is determined primarily by mass action and
therefore does not assess an impact of central nervous
system (CNS) 1,25D3 on insulin sensitivity, we next
used a hyperinsulinemic-euglycemic clamp to further
test whether i3vt 1,25D3 improves insulin sensitivity.
i3vt 1,25D3–treated animals required a markedly higher
glucose infusion rate throughout the clamp (Fig. 1C) to
maintain glucose levels matched to those of vehicle-treated
animals (Supplementary Fig. 1D). During the last
30 min of the clamp, 1,25D3-treated animals required
an almost sevenfold increase in glucose infusion rate,
which corresponded to a significant decrease in glucose
production (Fig. 1D) without differences in glucose clear-
ance (Fig. 1E). Since the liver is a major insulin-responsive
source of glucose, we evaluated hepatic expression levels
of key genes involved in gluconeogenesis. Phosphoenol-
pyruvate carboxykinase 1 (pck1), the rate-limiting enzyme
in gluconeogenesis, was decreased in 1,25D3-treated ani-
mals, but there was no difference in the expression of
glucose-6-phosphatase 3 (g6pc3) (Fig. 1F).
We then considered what population of VDR regulates
this potent CNS effect of vitamin D. Consistent with
previous research showing strong expression of VDR in
the human PVN (37), we observed abundant VDR staining
within the rodent PVN (Fig. 2A). i3vt 1,25D3 increased
c-fos expression in the PVN compared with vehicle but
had no effect when animals were pretreated with a VDR
antagonist (Fig. 2B and C). While we also saw VDR stain-
ing in the ventromedial nucleus of the hypothalamus,
another area known to have glucoregulatory functions,
there was only c-fos activation in the PVN. Thus, to de-
termine whether 1,25D3 could act in the PVN to regulate
glucose, we administered 1,25D3 directly into the PVN
(representative injection location in Supplementary Fig. 2A)
and found it decreased glucose excursion during an
i.p.GTT (Fig. 2D), evidenced by a decrease in the iAUC
analysis (Fig. 2F). In contrast, 1,25D3 did not decrease
glucose excursion when administered to rats that previ-
ously had a PVN injection of lentiviral short hairpin (sh)
RNA targeting the VDR (Fig. 2E and F). These effects were
independent of body weight, since there was no body
weight phenotype in the viral-treated rats (Supplemen-
tary Fig. 2B). While we were unable to quantify the
VDR knockdown in our lentiviral-treated rats, the atten-
uation of the 1,25D3-mediated glucose phenotype
suggests a role for the VDR in the PVN in glucose
regulation. Thus, we hypothesized that VDR in the PVN
has a physiological role in glucose homeostasis. We tested
this using a mouse model with a floxed VDR (21) and site-
specific knockdown of the VDR through an AAV-Cre
(VDRf/f/Cre) compared with a control virus (VDRf/f/
vector) bilaterally in the PVN. AAV-Cre injection de-
creased VDR expression by ;50% in the PVN (Supple-
mentary Fig. 2C). Interestingly, VDRf/f/Cre mice had an
increased glucose excursion during an i.p.GTT on HFD
(Fig. 2G and H) but not on standard chow (Supplementary
Fig. 2D). This effect was not secondary to weight differences
(Supplementary Fig. 2E) or an effect of the virus itself, as
there was no difference in glucose tolerance in C57Bl/6 mice
after AAV-Cre PVN injection (Supplementary Fig. 2F). It is
possible that the effect of the diet on glucose tolerance may
have been secondary to the aging of the animals, since
the GTTs were performed in the same animals at dif-
ferent time points. However, i3vt 1,25D3 improved glu-
cose tolerance in HFD-fed rats but not chow-fed rats of
equivalent ages (HFD 14 weeks [Fig. 1A] and chow
16 weeks [Supplementary Fig. 1B]), which supports a
differential effect of diet in the effects of vitamin D in
the brain. Together, these results identify a novel path-
way by which 1,25D3 and VDR may act to affect glucose
regulation in the brain and support the PVN as an in-
tegral location in these actions.
Vitamin D and Weight Regulation
Given the association of vitamin D deficiency and obesity,
we sought to determine whether vitamin D had central
effects on body weight or food intake. i3vt 1,25D3 did not
acutely alter food intake (Fig. 3A) but, when given chron-
ically to HFD-fed rats, caused a marked decrease in body
weight (Fig. 3B) and food intake (Fig. 3C). 1,25D3-treatment
specifically decreased fat mass without altering lean
mass (Fig. 3D). There were no differences in energy ex-
penditure between the groups (Fig. 3E). In addition, i3vt
1,25D3 did not cause a conditioned aversion to saccharin
(Fig. 3F). Smaller doses (0.132 and 0.066 mg/day) of
chronic i3vt 1,25D3 resulted in similar weight loss (Sup-
plementary Fig. 3A) and increases in peripheral calcium
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levels (Supplementary Fig. 3B). However, chronic subcu-
taneous delivery of 1,25D3 did not cause weight loss
(Supplementary Fig. 3C) despite a comparable increase
in peripheral calcium concentration (Supplementary
Fig. 3D). These results suggest that 1,25D3 can decrease
body weight through changes in food intake without
changes in energy expenditure and that these effects
are independent of aversive or hypercalcemic effects
of 1,25D3.
Given the potent effects of chronic 1,25D3 on food
intake, we hypothesized that 1,25D3 might regulate key
appetite-regulating neurons. We confirmed that VDRs
were present in the ARC (Fig. 4A) and discovered VDR
colocalized with 80.5 6 2.04% POMC-GFP–expressing
(Fig. 4B) and 86.9 6 5.0% NPY-GFP–expressing (Supple-
mentary Fig. 4A) neurons. 1,25D3 had direct transcrip-
tional effects in a hypothalamic cell line, Neuro2A,
increasing mRNA expression of cyp24a1 (Fig. 4C), a direct
target of the VDR (38). Pretreatment with a VDR genomic
antagonist attenuated the effects of 1,25D3 on cyp24a1,
indicating that 1,25D3 acted via VDR. More importantly,
we found that 1,25D3 directly activated POMC neurons.
In electrophysiology experiments with synaptic inputs
blocked, 1,25D3 activated 7/18 POMC neurons (represen-
tative tracing, Fig. 4D), causing a mean membrane poten-
tial change of 4.4 6 1.0 mV compared with 0.17 6
0.28 mV by vehicle treatment (Fig. 4E). The remaining
neurons had no response. Interestingly, without blockade
of synaptic inputs, 4/17 POMC cells were inhibited (Sup-
plementary Fig. 4C), indicating an additional population
of POMC neurons inhibited by 1,25D3.
DISCUSSION
The current results provide clear evidence that vitamin D
has potent CNS effects to improve glucose tolerance and
hepatic insulin sensitivity that do not occur when the
same small dose is administered peripherally. Previous
literature has shown vitamin D is important for insulin
secretion, specifically, that vitamin D increases insulin
secretion (10,39,40). Conversely, we found that central
administration of 1,25D3 caused a small reduction in pe-
ripheral insulin levels. It is unlikely that we missed the
effect of 1,25D3 on the insulin peak secondary to the
frequent sampling that occurred during the i.v.GTT.
Therefore, our data suggest that in addition to VDR ac-
tion in the b-cell, 1,25D3 may also improve glucose toler-
ance by insulin secretory–independent mechanisms. In
fact, our data strongly suggest that CNS 1,25D3 improves
glucose tolerance by improving hepatic insulin sensitivity
in HFD-fed rats.
Like humans (37), we found that rodents also have
strong VDR signaling in the PVN. In our animals, unilat-
eral direct injection of 1,25D3 into the PVN decreased
glucose excursions but had no effect in animals treated
with lentiviral VDR shRNA. This supports a direct action
of 1,25D3 via the VDR in the PVN to control glucose
Figure 3—Chronic hypothalamic 1,25D3 decreases body weight by decreasing food intake. A: Acute delivery of i3vt 1,25D3 (0.1 mg) did not
alter food intake in HFD-fed rats (n = 10–11/group). B and C: Chronic delivery of i3vt 1,25D3 (0.01 mg/h, 0.26 mg/day) decreased body
weight (B) and food intake (C) over 28 days (n = 3–4/group). D: After 28 days of chronic 1,25D3, fat mass, but not lean mass, was
decreased. E: After 3 days (3d) of chronic 1,25D3 delivery, when the animals were still body weight matched, average energy expenditure
was not different between the groups. F: No conditioned taste aversion occurred after 1,25D3 (0.1 mg) treatment. The positive control,
lithium chloride (LiCl), produced a positive conditioned taste aversion. hr, hour. *P < 0.05 vs. vehicle treatment (B–D) or water (F).
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levels, which is novel and consistent with research dem-
onstrating the importance of the PVN in glucose control
(18,41,42).
The effect of diet on the action of vitamin D in the
brain is important for both exogenous and endogenous
vitamin D action. First, in HFD but not chow conditions,
i3vt 1,25D3 improved glucose excursions. The lack of an
effect of 1,25D3 in a chow state is not surprising, since it
is difficult to improve upon an already normal glucose
tolerance. However, knockdown of the VDR in the PVN
resulted in a worsened GTT only in HFD-fed mice. Thus,
PVN VDRs are not necessary for normal glucose tolerance
in a chow-fed state, but in a state of excess nutrients act
to improve glucose tolerance. This may explain the asso-
ciation between low vitamin D levels and impaired glucose
tolerance in obese patients, since a lower vitamin D level
would theoretically lead to decreased VDR action in the
PVN.
With regard to energy homeostasis, our data show that
1,25D3 has actions within the brain to decrease food in-
take, thereby decreasing body weight and fat mass. One
previous report of intracerebral 1,25D3 also showed sig-
nificant weight loss over 6 days of treatment at a compa-
rable dose (;0.24 mg/day) (43). This anorexic effect of
i3vt 1,25D3 is not secondary to visceral illness, since
1,25D3 did not cause a conditioned taste aversion. We
ruled out hypercalcemia (a known cause of anorexia) as
a possible mechanism of weight loss, since peripherally
administered 1,25D3 increased calcium but did not
change body weight. Additionally, since only central
1,25D3, not peripheral 1,25D3, caused weight loss, this
ruled out a peripheral mechanism of action. Thus, i3vt
1,25D3–mediated weight loss is not likely to be due to
hypercalcemia or peripheral action of 1,25D3.
Although we demonstrated VDR within both the PVN
and ARC, there does not seem to be a role for the PVN in
weight regulation directly. There was no weight pheno-
type in the mice with bilateral PVN VDR knockdown.
Although it is possible that the importance of the PVN
in weight regulation was not seen secondary to only
achieving a ;50% knockdown, it is more likely that the
anorectic action of 1,25D3 lies within the ARC.
Our study is the first to show colocalization of VDR
with POMC and NPY neurons, which supports the
hypothesis that action of 1,25D3 in the brain to cause
weight loss may occur through VDR in the ARC. Using a
neuronal cell line, we demonstrated that 1,25D3 has VDR-
dependent transcriptional activity in neurons, since
1,25D3 treatment increased expression of a known VDR
target gene, cyp24a1, which was blocked with antagonism
Figure 4—1,25D3 depolarizes POMC neurons. A: VDRs are present in the ARC (310 magnification). B: POMC (green; first panel) and VDR
(red; middle panel) neurons colocalize (yellow; third panel). C: 1,25D3 increases cyp24a1 levels in Neuro2A cells. The VDR antagonist
ZK159222 attenuated the 1,25D3-induced expression of cyp24a1. D: Representative tracing of depolarization of a POMC neuron by
1,25D3. E: Change in membrane potential by 1,25D3 (n = 7) vs. vehicle (n = 11). Dashed lines outline the ARC. Scale bars = 100 mm.
*P < 0.05 vs. vehicle; #P < 0.05 vs. ZK159222.
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of the VDR. However, VDR also acts through nongenomic/
rapid-response pathways involving calcium channels (44).
The rapid depolarization of POMC cells by 1,25D3 indi-
cates a rapid-response action of 1,25D3. One possible
mechanism by which 1,25D3 may depolarize POMC cells
is through activation of transient receptor potential chan-
nels (TRPCs). Activation of TRPC5 cells can excite POMC
neurons (45). Although there are no published studies on
the effects of 1,25D3 on TRPC5 channels, there are pub-
lished reports of 1,25D3 activating TRPC3 channels (46).
Thus, future studies will examine the molecular mecha-
nism of action of 1,25D3 on POMC neurons. It is unclear
whether the food intake effects of 1,25D3 in the brain are
through rapid or genomic effects, since we saw food in-
take reduction in chronic, but not acutely, treated ani-
mals. Although we used well-handled animals, it is
possible that the acute effects of vitamin D on food intake
are masked by the unavoidable stress occurring in animals
after handling. Additionally, it is also possible that the
genomic and rapid effects are dependent upon one an-
other in vivo, as has been suggested by data on the rapid
effects of 1,25D3 on insulin secretion (44).
Our data provide elegant explanations for the conflict-
ing research surrounding vitamin D and obesity/diabetes.
First, our data clearly show the importance of central
action of vitamin D to affect glucose homeostasis or body
weight. Clinical trials have used a vitamin D precursor,
ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3),
and not the active compound, 1,25D3. Since 1,25D3 con-
centrations are tightly regulated in the body, supplemen-
tation of precursors may not lead to increases in 1,25D3
levels, particularly in the CNS. Previous research demon-
strates that both cholecalciferol and 1,25D3 have limited
uptake into the brain (20,47). Our own data show no effect
of peripheral 1,25D3 on weight loss or glucose but clearly
demonstrate that 1,25D3 can act within the brain to effect
change in glucose and weight regulation. Thus, peripheral
supplementation of a vitamin D derivative may have lim-
ited effects due to its limited access to the brain or the lack
of change in the concentration of central 1,25D3, despite
increases in peripheral levels of 25-hydroxyvitamin D. Sec-
ondly, our data clearly indicate the necessity of an obese
state to illuminate the effects of 1,25D3/VDR in the brain.
Paradoxically, the VDR-null animal has a lean phenotype
and on an HFD has decreased fat mass thought to occur
through an upregulation of uncoupling proteins (48,49).
The relevance of this effect is unclear in humans, since
vitamin D supplementation does not cause increases in
fat mass or decreases in energy expenditure. Additionally,
it is unknown what developmental compensation occurs,
especially in the brain, in a VDR-null animal. Our study
highlights the role of the VDR in adulthood without any
confounding developmental compensation, which is more
relevant to the clinical model of vitamin D deficiency asso-
ciated with obesity. Vitamin D supplementation, though,
has not improved glucose, insulin resistance, or adiposity
measures in overweight people in multiple studies (12–15).
Interestingly, trials showing beneficial effects of vitamin D
supplementation occurred in conjunction with diet modi-
fications and/or changes in BMI (4,16,17). Thus, it is pos-
sible that peripheral administration of vitamin D has
impaired transport into the brain in an obese setting,
which can be improved with diet modification or weight
loss. Overall, the contrast between the clinical studies and
our data underscores the necessity of understanding the
mechanisms underlying the association of low vitamin D
levels and obesity/diabetes in order to better inform clin-
ical trial design.
In conclusion, our studies are the first to show an
effect of 1,25D3 in the brain on both glucose and weight
regulation. We have demonstrated that these effects are
dependent upon action of vitamin D in distinct hypo-
thalamic nuclei. Additionally, we have demonstrated a
physiological and pharmacologic effect of vitamin D in
the PVN on glucose homeostasis. Our data support the
ARC as a possible site of action for 1,25D3 actions on
weight regulation. Further elucidation of the signaling
mechanisms involved in central VDR signaling are im-
portant for understanding the clinical association of vi-
tamin D deficiency and obesity/diabetes but also for
developing vitamin D derivatives that accentuate the
pharmacological effects on weight loss and improving
glucose homeostasis.
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